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HIV-1 treatment-failure patients are increasingly being initiated on second-line antiretroviral therapy. The case we describe is of a
treatment-failure patient who developed intractable chronic vulval ulceration presenting as immune reconstitution inﬂammatory
syndrome (IRIS), following complete viral suppression with second-line highly active antiretroviral treatment (HAART). To the
best of our knowledge, this is the ﬁrst reported case of intractable vulval ulceration IRIS in an HIV-1 treatment-failure patient.
1.Introduction
IRIS manifesting as genital ulcer disease (GUD) has been
documented in some reports [1, 2]. GUD as an IRIS event
in treatment-failure patients on the contrary has not been
documented. We describe a treatment-failure patient who
following complete viral suppression developed chronic vul-
val ulceration despite thorough and extensive investigations.
2. Case Presentation
A 35-year-old HIV-positive woman presented to the Infec-
tious Diseases Institute, Kampala, in February 2005 with
World Health Organization (WHO) stage III disease having
presented with a history of >10% weight loss and recurrent
upper respiratory tract infections (URTIs). Her nadir CD4+
count was 9cells/µL. She was initiated on HAART—with
a ﬁxed dose combination of lamivudine 150mg/stavudine
40mg/nevirapine 200mg (Triomune-40) one tablet twice
daily and cotrimoxazole prophylaxis to which she reported
100% adherence. After 1.5 years on HAART, she defaulted
on therapy for a period of 4 months. She subsequently began
receiving care from another HIV treatment centre where she
had a dual drug switch to tenofovir, emtricitabine (Truvada),
andnevirapine,towhichshecompliedwith100%adherence.
She continued treatment at that centre for 2 years. During
this period she had an initial rise in CD4+ cell count to a
peak of 389cells/µL which subsequently started decreasing
gradually both in absolute count and percentage.
At this juncture, she was referred back to our institute
where she was found with a CD4+ count of 30cells/µL
(2%). A decision was made to maintain her on truvada and
nevirapine following adherence counseling. A repeat CD4+
count8monthslatershowedafurtherdeclineintheabsolute
CD4+ count and percentage to 12cells/µL( 1 % ) ,w h i l es t i l l
on truvada and nevirapine. She had a detectable viral load
of 36,795copies/mL. She was then switched to abacavir,
zidovudine/lamivudine (Combivir), and lopinavir/ritonavir
(Alluvia) basing on possible development of K103N and
M184V mutations. A resistance proﬁle could not be done
due to the high costs involved. A repeat laboratory proﬁle
fourmonthslatershowedimmunologicalimprovementwith
a rise in CD4+ count and percentage to 75cells/µL( 4 % )a n d
an undetectable viral load of <400copies/mL.
The second-line HAART was well tolerated with sus-
tained viral suppression of <400copies/mL and immuno-
logical improvement to 209cells/µL (9%) six months later.
Four months after commencing second-line HAART and2 Case Reports in Obstetrics and Gynecology
achieving complete viral suppression, she presented with
complaints of vulval ulcers. Genital examination revealed
a 4cm superﬁcial right vulval ulcer. There were no other
signiﬁcant ﬁndings on systemic examination. Cryptococcal
antigen and Syphilis serology (Venereal Disease Research
Laboratories and Treponema pallidum haemagglutination
assay) were negative. Herpes simplex virus-2 serology could
not be done due to the high costs involved. Swabs from
the vulval ulcer and cervix were unremarkable. Two biopsies
revealed nonspeciﬁc chronic inﬂammation.
Treatment with oral acyclovir, famciclovir, ampiclox
(ampicillin/cloxacillin), cloxacillin, ceftriaxone, ﬂuconazole,
metronidazole,ciproﬂoxacin,doxycycline,nonsteroidalanti-
inﬂammatory drugs (NSAIDs), and topical hydrocortisone
cream was unsuccessful. A routine of oral prednisolone
40mg once daily given over ten days which was gradually
tapered oﬀ over a period of 4 weeks was repeated quarterly
with complete resolution approximately three years later.
Chlorhexidine and cetrimide (Hibitane) soaks were also
applied.
3. Discussion
GUD-IRIS has been shown to signiﬁcantly peak in the
ﬁrst month after HAART commencement [1]. Acute GUD-
IRIS has been commonly described as primarily syphilitic
and herpetiform [1, 3]. Adenovirus, cytomegalovirus, M.
tuberculosis,a n dM .avium complex have been implicated in
chronic GUD-IRIS in addition to herpes simplex [2, 4, 5].
IRIS may manifest as infectious or autoimmune clinical
eventspredominantlyoccurringintheﬁrst8weeksfollowing
HAART initiation with the exception of Graves’ disease
which occurs at a median time of 2 years [6–9]. Chronic
genital ulceration-IRIS has been described twice before [2,
5]. On the contrary, chronic genital ulceration IRIS lasting
overtwoyearsisrareandhasbeendescribedonlyoncebefore
[2]. Idiopathic chronic vulval ulceration IRIS, however, in
reconstituting HIV treatment failure patients has not been
described before, and, to the best of our knowledge, this is
theﬁrstreportedcaseofidiopathicchronicvulvalulceration-
IRIS in a reconstituting HIV treatment-failure patient.
In our patient, the cause of intractable chronic vulval
ulceration for over three years was idiopathic, following
extensive microbiological, histopathological investigations
and extensive treatment—with the use of antibiotics, antivi-
rals, NSAIDs, and steroids. It is therefore imperative that
clinicians are aware of chronic intractable genital ulceration-
IRIS that deﬁes extensive treatment and investigations when
HIV treatment-failure patients undergo immune reconstitu-
tion.
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